Navigating Pharmaceutical Industry in 2024
June, 2024 | Industry Report
The pharmaceutical industry has navigated through a turbulent landscape marked by the aftermath of the COVID-19 pandemic, escalating inflationary pressures, and geopolitical instability.
This period has necessitated rapid adaptation, fostering innovation, and prompting a re-evaluation of supply chain strategies, commercialisation models, and manufacturing operations.
As the industry transitions into 2024, the growth trajectory has experienced a notable deceleration compared to previous years.
Table of Contents
1. Introduction
According to Vamstar’s comprehensive analysis, leveraging our cutting-edge AI-based market intelligence platform, the global pharmaceutical industry’s total revenue reached a staggering $1.42 trillion in 2022.
However, the growth rate slowed from a remarkable 14.4% in 2021, a post-pandemic high, to a modest 5.2% in 2022 – the lowest level since 2017.
This downward trend has persisted into 2023, with revenues across major therapeutic areas and product segments exhibiting minimal to negligible growth compared to the previous year.
While numerous companies experienced a resurgence in the latter half of 2023, their revenue growth rates have yet to attain pre-pandemic levels.
Moreover, there is sustained pressure on the margins.
This deceleration can be attributed to several factors, including supply chain disruptions, pricing pressures, and evolving regulatory landscapes across various markets.
Changes Impacted The Industry
In 2023, several notable changes impacted the industry (to name a few)
The pharmaceutical industry is embracing the digital revolution with open arms, recognising the immense potential of cutting-edge technologies like artificial intelligence (AI) to streamline processes, drive innovation, and ultimately deliver better healthcare solutions to patients. The adoption of AI and digital tools is occurring across the entire value chain, from early-stage research and development to commercial operations and patient support.
One area where AI is making significant strides is in drug discovery and development. Pharmaceutical giants like Pfizer, Merck, and GlaxoSmithKline are leveraging AI-powered platforms to analyse vast amounts of data, identify promising drug targets, and optimise molecule design. For instance, Pfizer’s ‘IBM Watson for Drug Discovery’ partnership has accelerated the identification of potential drug candidates for immuno-oncology and Alzheimer’s disease. Similarly, Novartis has employed AI algorithms to predict the binding affinities of small molecules, streamlining the lead optimisation process.
Furthermore, AI is revolutionising clinical trials, enabling faster patient recruitment, remote monitoring, and data analysis. Companies like AstraZeneca and Sanofi are utilising AI-driven platforms to optimise trial designs, reducing costs and enhancing trial efficiency. Digital therapeutics, which combine AI-powered software with traditional therapies, are also gaining traction, offering personalised treatment plans and real-time monitoring for conditions like diabetes and mental health disorders.
Beyond research and development, AI is revolutionising commercial activities like evidence generation and management, market access, pricing, sales planning, and tendering in the pharmaceutical sector. Predictive analytics and machine learning algorithms are used to improve supply chain management, predict demand, and boost marketing strategies. Chatbots and virtual assistants, equipped with natural language processing (NLP), are enhancing customer support and patient engagement.
However, as with any disruptive technology, the adoption of AI in the pharmaceutical industry is not without challenges. Data quality, privacy concerns, regulatory hurdles, and the need for robust validation processes are key barriers that must be addressed. Industry leaders are actively collaborating with regulatory bodies and technology partners to establish guidelines and best practices for the responsible and ethical use of AI in healthcare.
The pharmaceutical industry recognises that embracing digitalisation and AI integration is not just a choice but a necessity to stay competitive and deliver innovative solutions that improve patient outcomes. By harnessing the power of these cutting-edge technologies, the industry is poised to accelerate drug development, enhance operational efficiencies, and ultimately contribute to a healthier future for all.
In 2023, the pharmaceutical industry faced significant challenges, including geopolitical tensions, supply chain disruptions, evolving regulations, and inflationary pressures, creating uncertainty across the sector.
Despite these obstacles, the industry remains strong, driven by an ageing global population, the shift towards home-based care, and the rising prevalence of chronic diseases. As the industry recovers from the pandemic, strategic priorities have emerged, focusing on restoring growth and enhancing investor confidence.
Pharmaceutical companies are navigating a complex environment, adapting operations and strategies to mitigate risks and capitalise on opportunities.
Geopolitical conflicts and trade tensions have disrupted supply chains, necessitating a reevaluation of sourcing strategies and supply chain resilience. Regulatory changes, especially in pricing and market access, require agile responses to ensure compliance and profitability.
The industry’s long-term prospects are promising, fueled by demographic shifts and the increasing burden of chronic diseases. An ageing global population and a rising middle class in emerging markets drive demand for innovative therapies and preventive healthcare solutions. The trend towards home-based care presents opportunities for developing patient-centric offerings and leveraging digital technologies.
As the industry recovers, companies are reassessing growth strategies, exploring portfolio optimisation, strategic partnerships, and digital transformation initiatives. Attracting and retaining investor confidence remains a priority, with a focus on demonstrating resilience, operational excellence, and a commitment to innovation and sustainable growth.
The COVID-19 pandemic exposed vulnerabilities in the pharmaceutical supply chain, causing disruptions and shortages of critical materials, APIs, and finished drugs. To mitigate future risks, the industry recognizes the need for a more resilient and diversified supply chain. According to a PhRMA survey, many pharmaceutical companies are now exploring a mix of specialized suppliers and full-service contract manufacturing organizations (CMOs) to enhance sourcing capabilities. Companies like Pfizer and Merck have partnered with CMOs to outsource the production of complex biologics and small molecule drugs, benefiting from their specialized manufacturing expertise.
Some companies are reducing their supplier base for cost optimization, while others are diversifying to mitigate risks associated with reliance on a single region or supplier. For instance, Novartis plans to establish a new manufacturing facility in the United States to ensure a stable supply of critical medicines. The primary challenges include extended lead times for raw materials and APIs, volatile pricing, and regulatory hurdles associated with offshore sourcing. Intellectual property protection and quality control concerns have prompted some companies to consider shifting manufacturing back to the United States or Europe or establishing in-house production for strategic products.
Broader challenges include workforce shortages in specialized areas like regulatory affairs and rising costs of raw materials and energy. Regulatory agencies such as the FDA and EMA have intensified scrutiny of supply chains, emphasizing robust quality management and transparency. To address these issues, pharmaceutical companies are leveraging digital technologies like blockchain for supply chain traceability, implementing advanced analytics for demand forecasting, and fostering strategic collaborations with academic institutions and government agencies to develop a skilled workforce and promote research in continuous manufacturing and advanced therapeutics.
The foreign exchange landscape in 2023 presented both challenges and opportunities for the industry. As a global enterprise, many companies are exposed to currency fluctuations that impact their top and bottom lines. However, proactive hedging strategies, coupled with strategic supply chain diversification and re-engineering efforts, enabled companies to mitigate the adverse effects of FX volatility.
In response to the inflationary pressures exacerbated by central banks’ monetary policies and the uneven economic recovery, many companies implemented judicious pricing adjustments across the product portfolio. These measures were essential to maintain the profitability and reinvest in the research and development of life-saving therapies.
The industry’s commitment to innovation and patient access remained unwavering despite the macroeconomic headwinds. By leveraging financial acumen and operational agility, most companies successfully navigated the turbulent landscape, ensuring the seamless supply of vital medications to patients worldwide.
The ongoing budgetary pressures and workforce challenges within healthcare systems, such as those in the EU and the US, underscore the critical need for cost-effective and efficient solutions from the pharmaceutical industry.
As public health spending tightens in the wake of the COVID-19 pandemic, exemplified by the discontinuation of emergency legislation in the EU, healthcare providers are increasingly seeking ways to optimise their resources while maintaining high-quality care standards.
This scenario presents a unique opportunity for pharmaceutical companies to step in with innovative products and services that can alleviate the burden on strained healthcare systems. For instance, the development of novel therapies that improve patient outcomes and reduce the need for prolonged hospitalisations or intensive care could potentially lead to significant cost savings for healthcare providers.
Moreover, the growing shortage of healthcare professionals, with the EU alone facing a deficit of 1.8 million workers that is projected to reach 4 million by 2030, highlights the importance of pharmaceutical solutions that can enhance workforce productivity and efficiency.
This could include digital health technologies that streamline workflows, remote patient monitoring tools that reduce the need for in-person visits, or disease management programs that empower patients to take a more active role in their care. By addressing these challenges head-on, pharmaceutical companies can position themselves as invaluable partners to healthcare systems, providing innovative solutions that not only drive revenue growth but also contribute to the long-term sustainability and resilience of public health infrastructures.
In recent times, pharmaceutical companies have faced increased operational costs (including higher SG&A costs), inflation, and rising interest rates, leading to workforce reductions, restructuring, and spinoffs.
Among the top pharmaceutical companies, approximately 80% have ongoing initiatives (launched post-COVID) to simplify their product portfolios, rationalise drug candidates, and streamline their operating models. The industry, particularly in Europe, saw a decline in profitability during 2022 and 2023, attributed to supply chain disruptions, higher energy and material costs, and wage inflation.
Experts recommend focusing on immediate operational efficiency and a long-term commitment to environmental, social, and governance (ESG) performance as remedies. For example, Pfizer Inc. announced a restructuring plan in 2022, which included cutting approximately 300 positions and discontinuing several early-stage drug development programs to streamline operations and reduce costs. Similarly, Novartis AG implemented a major overhaul of its business, spinning off its generics division, Sandoz, and focusing on innovative medicines and technology-driven therapies.
Certain pharmaceutical companies have successfully grown in revenue and profits by maintaining strategic focus, commercial realignment with technology adoption, innovation, efficient cost management, and robust ESG practices. For instance, AstraZeneca PLC has been investing heavily in oncology and cardiovascular research, leading to the approval of several blockbuster drugs, such as Tagrisso and Lynparza. The company has also embraced digital technologies, including artificial intelligence and machine learning, to accelerate drug discovery and development processes. Another example is Novo Nordisk A/S, a leading company in the diabetes care market, which has implemented various sustainability initiatives, including reducing its environmental footprint and improving access to affordable healthcare in underserved communities. The company’s commitment to ESG has been recognized by its inclusion in the Dow Jones Sustainability Index and other sustainability rankings.
As 2024 progresses, the pharmaceutical industry is expected to continue confronting these challenges, underscoring the need for both operational excellence and ESG integration to navigate the evolving market landscape effectively.
Companies that can strike the right balance between cost optimisation, strategic focus, innovation, and ESG practices are likely to emerge as winners in the long run.
The pharmaceutical industry is grappling with the implications of deglobalisation and reshoring trends, affecting various aspects of drug development and manufacturing. The investment landscape in pharmaceuticals is undergoing changes, with fluctuations in mergers and acquisitions, capital raising activities, and research and development investments across different regions.
For instance, in the United States, there has been a noticeable decline in cross-border pharmaceutical M&A deals, as companies reassess their global footprint and focus on domestic operations. Similarly, in Europe, capital raising for early-stage biotech firms has become more challenging, potentially hampering innovation.
These unique regional challenges demand rapid adaptation to economic slowdowns and shifts in market dynamics.
The COVID-19 pandemic highlighted the critical importance of pharmaceutical products and exposed vulnerabilities in global supply chains for essential medicines and active pharmaceutical ingredients (APIs). This experience has fueled discussions on supply chain resilience and strategic autonomy in the pharmaceutical sector.
Governments and industry leaders are exploring strategies to mitigate supply chain risks, potentially driving shifts towards more regionalised production networks. For example, several countries are incentivizing domestic manufacturing of critical drugs and APIs to reduce reliance on foreign suppliers during crises. As the pharmaceutical industry navigates these changes, companies may need to reconfigure their supply chains, manufacturing strategies, and investment priorities to align with the emerging landscape of deglobalization and reshoring.
Continue Reading
Register today to access full report and much more